newborn screening

Information about newborn screening

Published on October 12, 2007

Author: Pravez

Source: authorstream.com

Content

What’s New in Newborn Screening:  What’s New in Newborn Screening Kathy Tomashitis, MNS, RD Pediatric Screening Coordinator Division of Women and Children’s Services, SC DHEC Newborn Screening Expansion:  Newborn Screening Expansion Newborn screening began in South Carolina in the mid-1960’s with testing for phenylketonuria (PKU) Over the years, the test panel has expanded as improvements in technology occurred and as research indicated benefit of pre-symptomatic detection for specific disorders Newborn Screening-Why Expand the Test Panel:  Newborn Screening-Why Expand the Test Panel Several factors have lead to the current expansion Technological advances: increased use of tandem mass spectrometry (MS/MS) in newborn screening applications and improvement in the screening protocol for cystic fibrosis NO ADDITIONAL BLOOD NEEDED! Newborn Screening-Why Expand the Test Panel:  Newborn Screening-Why Expand the Test Panel Improved morbidity/mortality: research supports improved outcomes for pre-symptomatic identification of cystic fibrosis as well as disorders found through MS/MS; research has long recognized benefit of screening for biotinidase deficiency Cost benefit: research supports pre-symptomatic identification of fatty acid, amino acid and organic acid disorders found through MS/MS Newborn Screening-Why Expand the Test Panel:  Newborn Screening-Why Expand the Test Panel SC health care providers support expanded screening Survey of all newborn health care providers in SC conducted in 11/00: top three conditions recommended for expansion include cystic fibrosis, LCHADD ( a fatty acid oxidation disorder) and biotinidase deficiency Newborn Screening Advisory Committee recommended step-wise expansion to include cystic fibrosis, biotinidase deficiency and disorders found through MS/MS Newborn Screening-Why Expand the Test Panel:  Newborn Screening-Why Expand the Test Panel Growing awareness in disparity across states in conditions included in newborn screening test panel Expansion would provide SC infants with one of the most comprehensive test panels in US Consumer groups such as the March of Dimes support expanded test panels Newborn Screening Expansion:  Newborn Screening Expansion Current test panel includes screening for PKU, congenital hypothyroidism, galactosemia, congenital adrenal hyperplasia (CAH), medium chain acyl co-A dehydrogenase deficiency (MCADD) and hemoglobinopathies Newborn Screening Expansion-Cystic Fibrosis:  Newborn Screening Expansion-Cystic Fibrosis Cystic fibrosis is a genetic disorder that is found in 1:3500 Caucasian and 1:17,000 African American births CF is a recessive genetic disorder. Risk of recurrence is 1:4 with each pregnancy. In CF, the pulmonary and gastrointestinal systems are severely compromised. Newborn Screening Expansion-Cystic Fibrosis:  Newborn Screening Expansion-Cystic Fibrosis Fluids that are normally thin and slippery become thick and sticky Infections are treated aggressively Chest physiotherapy used to clear lungs Pancreatic enzymes used to aid digestion Newborn Screening Expansion-Cystic Fibrosis:  Newborn Screening Expansion-Cystic Fibrosis Screening will include measurement of immunoreactive trypsinogen (IRT) If the IRT is above a set level, a repeat IRT will be requested. If the IRT is still above normal limits on the second specimen, the infant will be referred to a CF center for sweat testing Newborn Screening Expansion-Cystic Fibrosis:  Newborn Screening Expansion-Cystic Fibrosis Sweat testing is still the “gold standard” for confirmation DNA testing for the most common CF mutations may be added to the screening protocol in the future Newborn Screening Expansion-Biotinidase Deficiency:  Newborn Screening Expansion-Biotinidase Deficiency Biotinidase deficiency is a recessive genetic disorder with a prevalence of 1:60,000 births (ethnic difference in prevalence not established) Like CF, risk of recurrence is 1:4 with each pregnancy Affected infants cannot utilize biotin, a vitamin found in foods, including breastmilk and infant formula Newborn Screening Expansion-Biotinidase Deficiency:  Newborn Screening Expansion-Biotinidase Deficiency Leads to developmental delay, seizures, hair loss, hearing loss, skin disorders and immunodeficiency Treated by giving infant biotin in the form of a crushed pill or capsule mixed into milk or food Screening will involve direct measurement of biotinidase False positive rates should be low Newborn Screening Expansion-Fatty Acid, Amino Acid and Organic Acid Disorders:  Newborn Screening Expansion-Fatty Acid, Amino Acid and Organic Acid Disorders Fatty acid, amino acid and organic acid disorders are individually rare, but occur with a combined frequency of 1:5000 to 1:6000 births Screening will include measurement of an acyl carnitine profile and an amino acid profile Newborn Screening Expansion-Fatty Acid, Amino Acid and Organic Acid Disorders:  Newborn Screening Expansion-Fatty Acid, Amino Acid and Organic Acid Disorders MS/MS is very precise, but interpretation is complex REMINDER--MS/MS can identify many, but not all metabolic disorders Newborn Screening Expansion-Fatty Acid Disorders:  Newborn Screening Expansion-Fatty Acid Disorders Most common FA disorder—MCADD—is part of the current test panel Expansion will add seven additional FA disorders All are recessive genetic disorders so risk of recurrence is 1:4 with each pregnancy Newborn Screening Expansion-Fatty Acid Disorders:  Newborn Screening Expansion-Fatty Acid Disorders Symptoms of most FA disorders Hypoketotic hypoglycemia Muscle weakness Seizures Sometimes cardiomyopathy Newborn Screening Expansion-Fatty Acid Disorders:  Newborn Screening Expansion-Fatty Acid Disorders Treatment of most FA disorders Avoid fasting Immediate medical attention when unable to eat usual diet Control type/amount of fat in diet depending upon the specific diagnosis Carnitine if indicated Cornstarch tube feeding at night if indicated Newborn Screening Expansion-Fatty Acid Disorders:  Newborn Screening Expansion-Fatty Acid Disorders Treatment (con’t) Ensure immunizations are up-to-date Treat infections promptly All patients should keep an “emergency protocol” letter with them at all times Newborn Screening Expansion-Fatty Acid Disorders:  Newborn Screening Expansion-Fatty Acid Disorders MINOR ILLNESSES CAN PRECIPITATE METABOLIC DECOMPENSATION IN AN INFANT/CHILD WITH A FA DISORDER!! Newborn Screening Expansion-Fatty Acid Disorders:  Newborn Screening Expansion-Fatty Acid Disorders Short chain acyl co-A dehydrogenase deficiency (SCADD) Estimated incidence is 1:40,000 to 1:100,000 Outcomes of known patients highly variable, but may be less severe than other FA disorders Newborn Screening Expansion-Fatty Acid Disorders:  Newborn Screening Expansion-Fatty Acid Disorders Long chain 3 OH co-A dehydrogenase deficiency/Trifunctional protein defect (LCHADD/TFP) Unknown incidence Differential diagnosis needed to separate LCHADD from TFP Cardiomyopathy and retinal changes HELLP/AFLP in 20% of affected pregnancies Newborn Screening Expansion-Fatty Acid Disorders:  Newborn Screening Expansion-Fatty Acid Disorders Very long chain acyl co-A dehydrogenase deficiency (VLCADD) Unknown incidence Some infants have cardiomyopathy Good outcome when treated presymptomatically Newborn Screening Expansion-Fatty Acid Disorders:  Newborn Screening Expansion-Fatty Acid Disorders Glutaric aciduria type II (GA II) Not thought to be rare, but incidence unknown Outcomes variable based upon phenotype Riboflavin supplementation useful in some mild cases Newborn Screening Expansion-Fatty Acid Disorders:  Newborn Screening Expansion-Fatty Acid Disorders Carnitine Palmitoyltransferase II deficiency (CPT II) Unknown incidence Muscle weakness, pain and myoglobinuria prompted by prolonged exercise 80% affected patients have been male Cardiac dysfunction rare Newborn Screening Expansion-Fatty Acid Disorders:  Newborn Screening Expansion-Fatty Acid Disorders Carnitine/acylcarnitine translocase deficiency (CACT) Thought to be very rare Long term outcome not clearly known Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders Expansion will add eleven OA disorders Most are recessive disorders so risk of recurrence is 1:4 with each pregnancy A few sub-types are X-linked so only males are affected, but females may show milder symptoms Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders Symptoms of most OA disorders Feeding problems Seizures Metabolic acidosis Lethargy Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders Treatment of most OA disorders Avoid fasting Immediate medical attention when unable to eat usual diet Control type/amount of protein in diet depending upon the specific diagnosis Carnitine if indicated Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders Treatment (con’t) Ensure immunizations are up-to-date Treat infections promptly All patients should keep an “emergency protocol” letter with them at all times Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders MINOR ILLNESSES CAN PRECIPITATE METABOLIC DECOMPENSATION IN AN INFANT/CHILD WITH AN OA DISORDER!! Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders Propionic acidemia (PA) Estimated incidence is 1:100,000 Oral antibiotics may be useful to decrease gut propionate Biotin if helpful Continuous overnight feeds helpful in some patients Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders Methylmalonic acidemia (MMA) Estimated incidence is 1:48,000 for B-12 non-responsive type; unknown incidence in other types Oral antibiotics may be useful to decrease gut propionate Vitamin B-12 if helpful Betaine if helpful Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders Isobutyrul co-A dehydrogenase deficiency (IBCDD) Thought to be very rare Long term outcome not clearly known, but appears to be good Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders Isovaleric acidemia (IVA) Estimated incidence is 1:230,000 Most have “sweaty sock” odor Glycine may be used in addition to carnitine Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders 2 methylbutyryl co-A dehydrogenase deficiency (2-MBCDD) Thought to be very rare Long term outcome not clearly known, but appears to be good Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders 3 methylcrotonyl co-A carboxylase deficiency (3-MCC) Estimated incidence is 1:50,000 Glycine may be used in addition to carnitine NBS result in infant may really be indicative of maternal 3-MCC Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders Beta ketothiolase deficiency Unknown incidence Urinary ketones should be monitored Moderate protein intake indicated Bicarbonate therapy often required long term Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders 3 methyl 3-OH glutaryl co-A lyase deficiency (HMGLD) Unknown incidence Diet may also be somewhat restricted in fat Supplemental glucose may be used Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders 3 methylglutaconyl co-A hydratase deficiency Thought to be very rare Type II is X-linked Protein restriction and supplemental carnitine may be useful for Type I Other types do not appear to respond to treatment Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders Multiple carboxylase deficiency (MCD) Estimated incidence is 1:87,000 Diet restriction NOT indicated Most cases are biotin responsive Biotin enhances the function of the carboxylase enzymes Not the same as biotinidase deficiency! Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders Glutaric aciduria type I (GA I) Estimated incidence is 1:40,000 Very important to proceed directly to diagnostic testing with any elevation Must treat fever aggressively Hospital admission mandatory for IV’s with any vomiting illness Newborn Screening Expansion-Organic Acid Disorders:  Newborn Screening Expansion-Organic Acid Disorders Glutaric aciduria type I (GA I) con’t Prone to subdural hemorrhages and retinal hemorrhages after minor head trauma (ie, fall when learning to walk) Can be misdiagnosed as child abuse May have profuse sweating Newborn Screening Expansion-Amino Acid Disorders:  Newborn Screening Expansion-Amino Acid Disorders Most common AA disorder—PKU—is part of the current test panel Expansion will add four additional AA disorders All are recessive genetic disorders so risk of recurrence is 1:4 with each pregnancy Symptoms and treatments vary by disorder Newborn Screening Expansion-Amino Acid Disorders:  Newborn Screening Expansion-Amino Acid Disorders Homocystinuria Estimated incidence is 1:200,000 Dislocated lens, marfanoid body type, thromboembolism Some patients are vitamin B 6 responsive MET restricted diet if B 6 non-responsive Betaine used after infancy Monitor folate/B 12 and supplement if needed Newborn Screening Expansion-Amino Acid Disorders:  Newborn Screening Expansion-Amino Acid Disorders Maple syrup urine disease (MSUD) Estimated incidence is 1:185,000 Severe ketoacidosis,  ammonia, sezuires, coma LEU restricted/ILE, VAL controlled diet Thiamin if responsive Newborn Screening Expansion-Amino Acid Disorders:  Newborn Screening Expansion-Amino Acid Disorders Citrullinemia Estimated incidence is 1:57,000  ammonia, lethargy, seizures, coma Protein restricted diet, ARG supplementation Na benzoate, Na phenylacetate, Na phenylbutyrate if indicated Aggressive treatment when ammonia levels  Newborn Screening Expansion-Amino Acid Disorders:  Newborn Screening Expansion-Amino Acid Disorders Argininosuccinic aciduria Estimated incidence is 1:70,000  ammonia, lethargy, seizures, coma Protein restriction, ARG supplementation Na benzoate, Na phenylacetate, Na phenylbutyrate if indicated Aggressive treatment when ammonia levels  Testing and Follow-up:  Testing and Follow-up State law requires all infants to be tested before hospital discharge regardless of their length of stay. DHEC laboratory performs all newborn screening tests. All results (normal, unacceptable and abnormal) are sent to the physician of record and the hospital or birthing center. Repeat tests are required when: one of the screening tests was abnormal, the initial sample was unacceptable, the initial sample was collected before 24 hours of age. Testing and Follow-up:  Testing and Follow-up Follow-up program calls physician of record when results are highly suggestive of a case. Follow-up program sends letter to physician of record to document phone call. Testing and Follow-up:  Testing and Follow-up Follow-up program sends letter to physician of record when results are outside of normal limits, but not highly suggestive of a case. Testing and Follow-up:  Testing and Follow-up By allowing name to be put on collection form, physician assumes all responsibility for ensuring repeat specimens are collected. Testing and Follow-up:  Testing and Follow-up If physician of record not providing care after hospital stay, he/she must notify DHEC as soon as possible so that local health department staff can ensure repeat specimens are collected. Challenges in Ensuring Complete Follow-up:  Challenges in Ensuring Complete Follow-up Name changes Incomplete demographic data Marking lab slip wrong (i.e. mark “PKU” when needed “T4”) Incorrect coding of MD or record Newborn Screening Expansion:  Newborn Screening Expansion FINAL WORDS—Never call newborn screening the “PKU test!!” Contact information general info: Kathy Tomashitis phone: 803-898-0619 email: [email protected] Newborn Screening Expansion:  Newborn Screening Expansion Contact information (con’t) Patient results: Linda Baker phone: 803-898-0593 fax: 803-898-0337 Medical consultant: Dr Bryant Fortner phone: 803-898-0362 email: [email protected]

Related presentations


Other presentations created by Pravez

BlueGene
19. 09. 2007
0 views

BlueGene

krul presentation1
22. 04. 2008
0 views

krul presentation1

GRP
17. 04. 2008
0 views

GRP

Howe1 25
14. 04. 2008
0 views

Howe1 25

Panview 3en
10. 04. 2008
0 views

Panview 3en

Global Trends and Prospects
09. 04. 2008
0 views

Global Trends and Prospects

2002 12 22 Christingle
07. 04. 2008
0 views

2002 12 22 Christingle

303 151renewableenergy
30. 03. 2008
0 views

303 151renewableenergy

mechanics of materials
05. 01. 2008
0 views

mechanics of materials

genetic recombination
06. 08. 2007
0 views

genetic recombination

DRAMA
19. 10. 2007
0 views

DRAMA

jong
19. 09. 2007
0 views

jong

C102 Bergallo
03. 10. 2007
0 views

C102 Bergallo

text cat tutorial
04. 10. 2007
0 views

text cat tutorial

Tornado Safety
07. 10. 2007
0 views

Tornado Safety

Switzerland Presentation
17. 10. 2007
0 views

Switzerland Presentation

CP15633
22. 10. 2007
0 views

CP15633

Hack lu cisco ddos
07. 10. 2007
0 views

Hack lu cisco ddos

DNA PowerPoint
15. 10. 2007
0 views

DNA PowerPoint

Membres du Bureau
23. 10. 2007
0 views

Membres du Bureau

23981
12. 10. 2007
0 views

23981

Joao LOBO ANTUNES
16. 10. 2007
0 views

Joao LOBO ANTUNES

Tomatoes
11. 12. 2007
0 views

Tomatoes

C avance
20. 11. 2007
0 views

C avance

Familias Unidas
22. 10. 2007
0 views

Familias Unidas

Module 20
23. 11. 2007
0 views

Module 20

media interview
08. 10. 2007
0 views

media interview

EO1 SysEngrColloq 03 02 04 Stu
05. 10. 2007
0 views

EO1 SysEngrColloq 03 02 04 Stu

hoffman arizona
30. 12. 2007
0 views

hoffman arizona

IA Emergency Preparedness
01. 01. 2008
0 views

IA Emergency Preparedness

Cohen NDIA
03. 01. 2008
0 views

Cohen NDIA

mathematicians
05. 01. 2008
0 views

mathematicians

hamm
23. 10. 2007
0 views

hamm

Prologue
15. 11. 2007
0 views

Prologue

geo inversion
19. 09. 2007
0 views

geo inversion

HIV AIDS Pandemic
06. 08. 2007
0 views

HIV AIDS Pandemic

Jeannie Armour Bearer
06. 08. 2007
0 views

Jeannie Armour Bearer

Hawaiian Cultural History
06. 08. 2007
0 views

Hawaiian Cultural History

jiscdigicon 07par1 1notay
06. 08. 2007
0 views

jiscdigicon 07par1 1notay

ESCpresentation
03. 01. 2008
0 views

ESCpresentation

Unit2 Lecture1
04. 01. 2008
0 views

Unit2 Lecture1

graficos ddet265
24. 10. 2007
0 views

graficos ddet265

Robin Room
07. 01. 2008
0 views

Robin Room

jageps
06. 08. 2007
0 views

jageps

Jewish Initiation
06. 08. 2007
0 views

Jewish Initiation

HIUG
06. 08. 2007
0 views

HIUG

singers
20. 02. 2008
0 views

singers

HGM2006 S7 01 Pedersen
06. 08. 2007
0 views

HGM2006 S7 01 Pedersen

ModuleA5Session3
04. 03. 2008
0 views

ModuleA5Session3

hlt 2004
06. 08. 2007
0 views

hlt 2004

Brussel Health Kuopio KPoutanen
20. 03. 2008
0 views

Brussel Health Kuopio KPoutanen

CIO Main Screens Sydney Final
26. 03. 2008
0 views

CIO Main Screens Sydney Final

Movimento Pentecostal 2 ok
01. 10. 2007
0 views

Movimento Pentecostal 2 ok

guyana csw 2000
06. 08. 2007
0 views

guyana csw 2000

05f 1800 lys a3
19. 02. 2008
0 views

05f 1800 lys a3

Guze 07 Sarah Pedersen
06. 08. 2007
0 views

Guze 07 Sarah Pedersen

Normativa Vittoria marzo06
18. 06. 2007
0 views

Normativa Vittoria marzo06

new Media Activism
18. 06. 2007
0 views

new Media Activism

LKD ACPC2005autoshow
18. 06. 2007
0 views

LKD ACPC2005autoshow

LAS VEGAS PRESENTATION
18. 06. 2007
0 views

LAS VEGAS PRESENTATION

lab storia marcia mille
18. 06. 2007
0 views

lab storia marcia mille

Kreutz
18. 06. 2007
0 views

Kreutz

kinder verzamelingen 05
18. 06. 2007
0 views

kinder verzamelingen 05

kereso halo
18. 06. 2007
0 views

kereso halo

japan overview
18. 06. 2007
0 views

japan overview

jaden
18. 06. 2007
0 views

jaden

2007 dossier pere
18. 06. 2007
0 views

2007 dossier pere

2005 NAIDC Promo
18. 06. 2007
0 views

2005 NAIDC Promo

1212 SLIDES CSR Briefing final1
18. 06. 2007
0 views

1212 SLIDES CSR Briefing final1

07PSPTribute
18. 06. 2007
0 views

07PSPTribute

bioprez1
17. 11. 2007
0 views

bioprez1

Chapter18
19. 09. 2007
0 views

Chapter18

LUXva
18. 06. 2007
0 views

LUXva

f38 math meets maps
15. 06. 2007
0 views

f38 math meets maps

Extraction of Beam into TT40
15. 06. 2007
0 views

Extraction of Beam into TT40

Experiencing HaShem
15. 06. 2007
0 views

Experiencing HaShem

Euthyphro
15. 06. 2007
0 views

Euthyphro

ethnic humor
15. 06. 2007
0 views

ethnic humor

Essentials of UP 1
15. 06. 2007
0 views

Essentials of UP 1

Catv2
15. 06. 2007
0 views

Catv2

Cartoons pig
15. 06. 2007
0 views

Cartoons pig

cartoons stick men 1
15. 06. 2007
0 views

cartoons stick men 1

attr 159897 115
12. 10. 2007
0 views

attr 159897 115

kskee
19. 09. 2007
0 views

kskee

akrishna
28. 11. 2007
0 views

akrishna

18cm
18. 06. 2007
0 views

18cm

BrazilSeminar
22. 10. 2007
0 views

BrazilSeminar

PRSarahL
13. 03. 2008
0 views

PRSarahL

prezent1
15. 11. 2007
0 views

prezent1

power law tut
19. 09. 2007
0 views

power law tut

EthicalEgoism
15. 06. 2007
0 views

EthicalEgoism

petersuter ppt
17. 10. 2007
0 views

petersuter ppt

Internet Equivalence
06. 08. 2007
0 views

Internet Equivalence

slogany
21. 11. 2007
0 views

slogany

Blue Chalkboard
19. 09. 2007
0 views

Blue Chalkboard

Gogol at the Edge of Being
27. 09. 2007
0 views

Gogol at the Edge of Being

ScottKsander10 10
02. 11. 2007
0 views

ScottKsander10 10

labrolazegbe
18. 06. 2007
0 views

labrolazegbe

chap12sp06 groups day 3
14. 12. 2007
0 views

chap12sp06 groups day 3

Resources Potpourri Final2006
26. 10. 2007
0 views

Resources Potpourri Final2006

powers tami portia topics
19. 09. 2007
0 views

powers tami portia topics

APGridPMA EU 200605
10. 10. 2007
0 views

APGridPMA EU 200605

Higgins Webinar Slides 070425
19. 09. 2007
0 views

Higgins Webinar Slides 070425